3809-93-6

Basic information

• Product Name: 2-Methyl-4H-pyrido[3,2-e][1,3]oxazin-4-one
• Synonyms: 2-Methyl-4H-pyrido[3,2-e][1,3]oxazin-4-one;2-Methyl-4H-pyrido[2,3-d][3,1]oxazin-4-one;2-methyl-4H-pyrido[2,3-d][1,3]oxazin-4-one
• CAS NO: 3809-93-6
• Molecular Formula: C₈H₆N₂O₂
• Molecular Weight: 162.14544
• Mol File: 3809-93-6.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-Methyl-4H-pyrido[3,2-e][1,3]oxazin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methyl-4H-pyrido[3,2-e][1,3]oxazin-4-one(3809-93-6)
• EPA Substance Registry System: 2-Methyl-4H-pyrido[3,2-e][1,3]oxazin-4-one(3809-93-6)

Safety Data

• Hazardous Substances Data: 3809-93-6(Hazardous Substances Data)

Upstream product

• 5345-47-1 2-aminopyridin-3-carboxylic acid 
• 108-24-7 acetic anhydride 
• 14667-47-1 methyl 2-aminonicotinate 
• 2942-59-8 2-chloronicotinic acid 
• 2398-81-4 Nicotinic acid N-oxide 
• 59-67-6 nicotinic acid 

Downstream Products

• 14133-24-5 2-methyl-3-(2-methylphenyl)pyrido<2,3-d>pyrimidin-4(3H)-one 
• 28279-12-1 2-methylpyrido[2,3-d]pyrimidin-4(3H)-one 
• 1186189-28-5 ethyl 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxylate 
• 94243-07-9 2-(p-Methoxystyryl)-3-phenylpyrido<2,3-d>pyrimidin-4(3H)-one 
• 14841-97-5 2-Methyl-3-(2'-methyl-3'-chlorphenyl)-4-oxo-3,4-dihydropyrido<2,3-d>pyrimidin 
• 54716-26-6 3-(4-chloro-phenyl)-2-methyl-3H-pyrido[2,3-d]pyrimidin-4-one 

Relevant articles and documents

Reactions of 2-methyl-4H-pyrido[2,3-d][3,1]oxazin-4-one with active methylene compounds: A new efficient route to 3-substituted 4-hydroxy-1,8-naphthyridin-2(1H)-ones

3-Substituted 1,8-naphthyridine-2,4-diones, compounds of very important pharmaceutical use, have been synthesized using a new efficient route. The reaction of 2-methyl-4H-pyrido-[2,3-d][3,1]oxazin-4-one, 1b, with active methylene compounds furnishes the 1-acetyl-3-substituted-4-hydroxy-1,8-naphthyridin-2-ones 3-5, in good yields. In the case of cyanoacetic esters the intermediate C-acylation compounds 7 and 8 were isolated and subsequently cyclized to 1-acetyl-3-cyano-4-hydroxy-1,8-naphthyridin-2-one 6. Spectral data and physical characteristics for all compounds are reported.

Atroposelective Desymmetrization of Resorcinol-Bearing Quinazolinones via Cu-Catalyzed C–O Bond Formation

Enantioselective Cu-catalyzed C–O cross coupling reactions yielding atropisomeric resorcinol-bearing quinazolinones have been developed. Utilizing a new guanidinylated dimeric peptidic ligand, a set of products were generated in good yields with excellent

Chemical Space Exploration around Thieno[3,2- d]pyrimidin-4(3 H)-one Scaffold Led to a Novel Class of Highly Active Clostridium difficile Inhibitors

Clostridium difficile infection (CDI) is the leading cause of healthcare-associated infection in the United States. Therefore, development of novel treatments for CDI is a high priority. Toward this goal, we began in vitro screening of a structurally diverse in-house library of 67 compounds against two pathogenic C. difficile strains (ATCC BAA 1870 and ATCC 43255), which yielded a hit compound, 2-methyl-8-nitroquinazolin-4(3H)-one (2) with moderate potency (MIC = 312/156 μM). Optimization of 2 gave lead compound 6a (2-methyl-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one) with improved potency (MIC = 19/38 μM), selectivity over normal gut microflora, CC50s > 606 μM against mammalian cell lines, and acceptable stability in simulated gastric and intestinal fluid. Further optimization of 6a at C2-, N3-, C4-, and C7-positions resulted in a library of >50 compounds with MICs ranging from 3 to 800 μM against clinical isolates of C. difficile. Compound 8f (MIC = 3/6 μM) was identified as a promising lead for further optimization.